Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE1831 in Relapsed/Refractory CD20-expressing B-cell Malignancies
NCT05653271Phase 1Completed
- Sponsor
- Acepodia
- Start
- Jan 2023
- Primary completion
- Mar 2026
- Modality
- Antibody-Drug Conjugates (ADCs), Native Immune Cells
- Countries
- 3
01
Overview
Phase 1, open-label trial of ACE1831 in non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Acepodia. Primary endpoints: Adverse Events at 2 years, ECOG Performance Status at 1 year and 6 more. Started Jan 2023; status: completed.
02
Drugs
ACE1831
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05653271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05653271.